Raina M Ferzoco, MD
Hematology/Oncology · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 8
- 4 carriers
- Offices
- 3
Offices
3 locations · Monterey Bay Oncology A Medical Corporation · Dignity Health Medical Foundation
Looking this up.
Hospitals listed: 051526 · Dominican Hospital · Stanford Health Care · Watsonville Community Hospital. That is not proof they admit you there this week.
Plans that list them
8 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ferzoco’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
8 of 8 plans
| Advantage Care (HMO) | Align Senior Care | Listed | Oct 1, 2026 |
| Premier Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Senior Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A159773 · Current
Licensed to practise in California · since 2018 · expires 2028-12-31 · University of Florida College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Dominican HospitalSanta Cruz, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 68% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Postoperative sepsis rate: 11.66 (8.02 to 15.3) · 412 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.168, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.169, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.489, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Watsonville Community HospitalWatsonville, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPatients rate it 3 of 5 · 66% would definitely recommend itOverall rating: 2 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for Dominican Hospital
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative sepsis rateComplications and deaths | 11.66 (8.02 to 15.3) · 412 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.168 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.169 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.489 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0.06 to 1.95) · 1,248 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.85 to 1.43) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 134.37 (94.33 to 174.41) · 132 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 54 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 137 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 228 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 534 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.8 · 491 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 278 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 2,973 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 7,510 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,695 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.42 (1.44 to 5.4) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.26 (0 to 2.76) · 436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.85 (0.4 to 3.29) · 1,474 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.73 (3 to 14.46) · 437 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.03) · 343 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.17) · 6,336 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.615 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.937 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 212 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 505 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 45 · 237 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.5 · 594 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.9 · 510 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 473 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.4 to 7.8) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13 (9.4 to 17.7) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.7 · 43 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9.4 to 15.4) · 1,585 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 390 cases | No different | Jan 2024 – Dec 2024 |
What patients said (774 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 32% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Watsonville Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 4 the same, 2 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0 to 2.08) · 194 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.44 to 1.32) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.6 · 98 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.7 · 210 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.5 · 74 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 604 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 1,963 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,942 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.64 to 5.66) · 232 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.39) · 33 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.24 (0.54 to 3.95) · 216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.86 (0 to 18.76) · 37 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.09 (0.81 to 9.36) · 32 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.21 to 3.24) · 71 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.35 (0 to 1.35) · 1,464 cases | No different | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.351 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 82 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 52.2 · 119 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 31.4 · 221 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 182 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 28 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.5 to 17.2) · 311 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 46 cases | No different | Jan 2024 – Dec 2024 |
What patients said (264 patients answered, 12% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 77% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 66% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$141,262
Medicare paid this office $141,262 for 289 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 182 | $42,309 | $107 |
| Long return visit (40+ min) | 78 | $37,838 | $151 |
| New patient visit (60+ min) | 59 | $10,816 | $183 |
| Short return visit (20+ min) | 77 | $6,778 | $77 |
| New patient visit (45+ min) | 13 | $1,470 | $113 |
See all 7 services
| Return visit (30+ min) | 182 | $42,309 | $107 |
| Long return visit (40+ min) | 78 | $37,838 | $151 |
| New patient visit (60+ min) | 59 | $10,816 | $183 |
| Short return visit (20+ min) | 77 | $6,778 | $77 |
| New patient visit (45+ min) | 13 | $1,470 | $113 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 33 | $578 | $12 |
| Injection of drug or substance under skin or into muscle | 17 | $427 | $12 |
Who their Medicare patients are
289 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 14% · Women 60% · Also on Medicaid 27% · Health risk score 1.67. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 67% · Cancer 43% · Diabetes 24% · Chronic kidney disease 21% · Depression 21% · Coronary heart disease 19% · Atrial fibrillation 18% · Heart failure 13% · COPD 13% · Stroke 7%.
The office billed $553,024, Medicare allowed $184,591 and paid $141,262; for 7,367 services of 30 kinds; $36,713 of it was for drugs given in the office and $104,549 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 289 | 7,367 | 75 | 1.67 | $553,024 | $141,262 |
| 2023 | 285 | 13,979 | 75 | 1.73 | $752,500 | $198,173 |
| 2022 | 309 | 42,793 | 75 | 1.97 | $1,152,017 | $354,182 |
| 2021 | 244 | 20,239 | 74 | 1.62 | $1,304,484 | $424,424 |
| 2020 | 198 | 2,438 | 74 | 1.69 | $477,241 | $135,687 |
| 2019 | 260 | 18,417 | 74 | 1.89 | $1,344,228 | $297,411 |
| 2018 | 209 | 58,852 | 74 | 2.09 | $3,128,797 | $662,032 |
| 2017 | 203 | 75,582 | 73 | 2.28 | $3,772,442 | $782,926 |
| 2016 | 117 | 15,590 | 72 | 2.08 | $618,093 | $131,848 |
| 2015 | 61 | 130 | 72 | 1.68 | $16,904 | $11,201 |
| 2014 | 42 | 144 | 73 | 2.33 | $15,660 | $11,021 |
| 2013 | 11 | 45 | 74 | 1.63 | $4,879 | $3,526 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Long return visit (40+ min) | 96 | $51,752 | $151 |
| Return visit (30+ min) | 192 | $43,801 | $107 |
| Short return visit (20+ min) | 86 | $8,276 | $69 |
| New patient visit (60+ min) | 44 | $7,360 | $167 |
| New patient visit (45+ min) | 22 | $2,950 | $134 |
| Telephone medical discussion with physician, 11-20 minutes | 19 | $1,441 | $63 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 16 | $1,213 | $76 |
| Injection of drug or substance under skin or into muscle | 28 | $901 | $12 |
| Administration of influenza virus vaccine | 17 | $580 | $34 |
2022: 11 services
| Long return visit (40+ min) | 112 | $74,622 | $154 |
| Return visit (30+ min) | 196 | $43,349 | $110 |
| New patient visit (60+ min) | 65 | $11,617 | $179 |
| Short return visit (20+ min) | 73 | $6,895 | $73 |
| New patient visit (45+ min) | 20 | $2,405 | $120 |
| Injection of drug or substance under skin or into muscle | 30 | $2,118 | $13 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,937 | $161 |
| Telephone medical discussion with physician, 11-20 minutes | 17 | $1,471 | $77 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 20 | $1,405 | $70 |
| Administration of influenza virus vaccine | 21 | $714 | $34 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 14 | $45 | None |
2021: 11 services
| Long return visit (40+ min) | 91 | $68,642 | $159 |
| Return visit (30+ min) | 182 | $49,739 | $107 |
| New patient visit (60+ min) | 101 | $18,818 | $186 |
| Short return visit (20+ min) | 44 | $3,662 | $76 |
| Telephone medical discussion with physician, 21-30 minutes | 18 | $2,567 | $99 |
| New patient visit (45+ min) | 13 | $1,930 | $148 |
| Telephone medical discussion with physician, 11-20 minutes | 16 | $1,719 | $78 |
| Injection of drug or substance under skin or into muscle | 26 | $1,453 | $13 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 18 | $1,129 | $63 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 12 | $403 | $29 |
| Administration of influenza virus vaccine | 18 | $330 | $18 |
2020: 7 services
| Return visit (30+ min) | 135 | $40,544 | $89 |
| Long return visit (40+ min) | 52 | $13,234 | $124 |
| New patient visit (60+ min) | 66 | $11,221 | $170 |
| New patient visit (45+ min) | 35 | $4,312 | $123 |
| Telephone medical discussion with physician, 21-30 minutes | 25 | $4,025 | $96 |
| Telephone medical discussion with physician, 11-20 minutes | 28 | $3,798 | $67 |
| Short return visit (20+ min) | 44 | $3,246 | $64 |
2019: 16 services
| Return visit (30+ min) | 126 | $25,899 | $86 |
| New patient visit (60+ min) | 60 | $10,604 | $177 |
| New patient visit (45+ min) | 50 | $6,954 | $139 |
| Long return visit (40+ min) | 38 | $6,480 | $122 |
| Administration of chemotherapy into vein, 1 hour or less | 33 | $4,669 | $114 |
| Short return visit (20+ min) | 44 | $2,760 | $55 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 25 | $1,107 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 16 | $1,060 | $56 |
| Blood test, comprehensive group of blood chemicals | 23 | $357 | $12 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 29 | $355 | $8 |
| Injection of drug or substance under skin or into muscle | 13 | $218 | $14 |
| Infusion into a vein for hydration, each additional hour | 12 | $195 | $11 |
| Injection of additional new drug or substance into vein | 11 | $188 | $13 |
| Insertion of needle into vein for collection of blood sample | 24 | $97 | $3 |
| Infusion, normal saline solution , 1000 cc | 13 | $34 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 20 | $18 | None |
2018: 31 services
| Injection, pegfilgrastim, 6 mg | 13 | $84,401 | None |
| Injection, ferric carboxymaltose, 1 mg | 20 | $17,369 | None |
| Administration of chemotherapy into vein, 1 hour or less | 49 | $13,119 | $112 |
| Return visit (30+ min) | 86 | $11,654 | $82 |
| Unclassified drugs | 23 | $6,465 | None |
| Injection, palonosetron hcl, 25 mcg | 20 | $5,719 | None |
| Short return visit (20+ min) | 58 | $4,319 | $55 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 39 | $3,346 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 33 | $2,842 | $58 |
| Long return visit (40+ min) | 18 | $2,158 | $114 |
| Administration of additional new drug or substance into vein, 1 hour or less | 17 | $2,117 | $54 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $2,105 | $64 |
| Blood test, comprehensive group of blood chemicals | 45 | $1,624 | $13 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 50 | $1,552 | $9 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 12 | $1,184 | $25 |
| New patient visit (30+ min) | 14 | $1,174 | $84 |
| Injection of additional new drug or substance into vein | 32 | $961 | $14 |
| Injection, zoledronic acid, 1 mg | 13 | $818 | None |
| Administration of chemotherapy into vein, each additional hour | 11 | $815 | $25 |
| Infusion into a vein for hydration, 31-60 minutes | 13 | $782 | $37 |
| Injection of drug or substance under skin or into muscle | 26 | $653 | $16 |
| Infusion into a vein for hydration, each additional hour | 18 | $633 | $11 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $516 | $25 |
| Insertion of needle into vein for collection of blood sample | 48 | $363 | $3 |
| Application of on-body injector for under skin injection | 12 | $343 | $16 |
| Iron binding capacity | 11 | $148 | $11 |
| Iron level | 11 | $110 | $8 |
| Infusion, normal saline solution , 1000 cc | 20 | $87 | None |
| Injection, granisetron hydrochloride, 100 mcg | 16 | $80 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 34 | $61 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 11 | $13 | None |
2017: 32 services
| Injection, pegfilgrastim, 6 mg | 22 | $135,554 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 14 | $31,321 | None |
| Administration of chemotherapy into vein, 1 hour or less | 65 | $17,747 | $110 |
| Injection, palonosetron hcl, 25 mcg | 31 | $12,618 | None |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 19 | $9,720 | $1 |
| Return visit (30+ min) | 50 | $7,614 | $80 |
| Short return visit (20+ min) | 57 | $4,840 | $56 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 58 | $4,783 | $24 |
| Long return visit (40+ min) | 29 | $3,949 | $113 |
| Injection of additional new drug or substance into vein | 46 | $2,951 | $18 |
| Administration of additional new drug or substance into vein, 1 hour or less | 18 | $2,587 | $52 |
| Injection of drug or substance under skin or into muscle | 48 | $2,174 | $20 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 25 | $1,921 | $53 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 44 | $1,634 | $10 |
| Blood test, comprehensive group of blood chemicals | 36 | $1,418 | $14 |
| Infusion into a vein for hydration, 31-60 minutes | 19 | $1,333 | $46 |
| New patient visit (30+ min) | 15 | $1,253 | $84 |
| Injection, zoledronic acid, 1 mg | 18 | $1,102 | None |
| Administration of chemotherapy into vein, each additional hour | 16 | $919 | $22 |
| Infusion into a vein for hydration, each additional hour | 26 | $700 | $12 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $568 | $26 |
| Unclassified drugs | 19 | $277 | None |
| Injection, cisplatin, powder or solution, 10 mg | 11 | $257 | None |
| Cyanocobalamin (vitamin b-12) level | 12 | $228 | $19 |
| Insertion of needle into vein for collection of blood sample | 36 | $202 | $3 |
| Red blood count automated, with additional calculations | 15 | $120 | $7 |
| Injection, granisetron hydrochloride, 100 mcg | 13 | $105 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 56 | $103 | None |
| Infusion, normal saline solution , 1000 cc | 26 | $90 | None |
| Lactate dehydrogenase (enzyme) level | 11 | $57 | $4 |
| Injection, diphenhydramine hcl, up to 50 mg | 21 | $27 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 13 | $22 | None |
2016: 12 services
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 11 | $16,651 | None |
| Long return visit (40+ min) | 40 | $7,064 | $99 |
| Return visit (30+ min) | 29 | $3,350 | $78 |
| Administration of chemotherapy into vein, 1 hour or less | 20 | $3,000 | $107 |
| Injection, palonosetron hcl, 25 mcg | 11 | $2,332 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 20 | $1,013 | $24 |
| Short return visit (20+ min) | 13 | $706 | $54 |
| Injection of additional new drug or substance into vein | 17 | $480 | $18 |
| Injection of drug or substance under skin or into muscle | 15 | $461 | $20 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 12 | $187 | $10 |
| Insertion of needle into vein for collection of blood sample | 11 | $44 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 19 | $21 | None |
2015: 2 services
| Return visit (30+ min) | 40 | $6,527 | $80 |
| Long return visit (40+ min) | 22 | $3,009 | $107 |
2014: 1 service
| Return visit (30+ min) | 31 | $3,683 | $78 |
Medicaid work
$15,051 in 2024
Medicaid paid $15,051 for 196 billed services this clinician did in 2024, up to 22 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 141 | $9,145 |
| Long return visit (40+ min) | 55 | $5,906 |
| 2024 | 196 | 2 | 22 | $15,051 |
| 2023 | 563 | 5 | 29 | $52,265 |
| 2022 | 334 | 2 | 25 | $39,068 |
| 2021 | 242 | 2 | 29 | $25,200 |
| 2020 | 239 | 1 | 28 | $20,259 |
| 2019 | 31 | 1 | 14 | $966 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 229 | $28,029 |
| Return visit (30+ min) | 259 | $22,759 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 34 | $1,138 |
| COMPREHENSIVE METABOLIC PANEL | 15 | $174 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 26 | $165 |
2022
| Long return visit (40+ min) | 154 | $22,224 |
| Return visit (30+ min) | 180 | $16,844 |
2021
| Return visit (30+ min) | 174 | $15,715 |
| Long return visit (40+ min) | 68 | $9,485 |
2020
| Return visit (30+ min) | 239 | $20,259 |
2019
| Return visit (30+ min) | 31 | $966 |
Drugs they prescribed that Part D paid
$3,660,375
Pharmacies billed $3,660,375 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 8% of their Part D prescriptions (78 of 972) in 2024. Above the middle of the specialty; the typical hematology-oncology clinician is at 5%. Long-acting opioids: 18% of their opioid prescriptions.
728 generic and 244 brand-name prescriptions · $3,660,375 in drug cost · 26 antibiotic prescriptions to 15 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Revlimid | 36 | $761,874 | $21,163 |
| Lenalidomide | 38 | $480,136 | $12,635 |
| Brukinsa | 25 | $349,404 | $13,976 |
| Imbruvica | 23 | $318,117 | $13,831 |
| Lynparza | 19 | $288,693 | $15,194 |
See all 33 drugs
| Revlimid | 36 | $761,874 | $21,163 |
| Lenalidomide | 38 | $480,136 | $12,635 |
| Brukinsa | 25 | $349,404 | $13,976 |
| Imbruvica | 23 | $318,117 | $13,831 |
| Lynparza | 19 | $288,693 | $15,194 |
| Tasigna | 14 | $285,495 | $20,392 |
| Jakafi | 14 | $224,418 | $16,030 |
| Yonsa | 13 | $135,807 | $10,447 |
| Eliquis | 22 | $17,177 | $781 |
| Anastrozole | 51 | $1,433 | $28 |
| Exemestane | 11 | $1,356 | $123 |
| Tamoxifen Citrate | 33 | $1,158 | $35 |
| Letrozole | 26 | $712 | $27 |
| Prochlorperazine Maleate | 39 | $693 | $18 |
| Hydroxyurea | 29 | $498 | $17 |
| Diphenoxylate-Atropine | 16 | $479 | $30 |
| Ondansetron | 41 | $429 | $10 |
| Dexamethasone | 26 | $381 | $15 |
| Gabapentin | 23 | $365 | $16 |
| Hydrocodone-Acetaminophen | 14 | $341 | $24 |
| Oxycodone | 22 | $311 | $14 |
| Albuterol Sulfate Hfa | 13 | $307 | $24 |
| Prednisone | 28 | $223 | $8 |
| Tramadol | 13 | $209 | $16 |
| Potassium Chloride | 13 | $201 | $15 |
| Morphine Sulfate Er | 14 | $187 | $13 |
| Trazodone | 20 | $135 | $7 |
| Mirtazapine | 13 | $117 | $9 |
| Lorazepam | 21 | $76 | $4 |
| Pantoprazole | 13 | $56 | $4 |
| Baclofen | 13 | $42 | $3 |
| Escitalopram | 11 | $34 | $3 |
| Buspirone | 17 | $29 | $2 |
Year by year
| 2024 | 972 | 135 | 8% (78) | 25% | $3,660,375 |
| 2023 | 1,099 | 151 | 7% (80) | None | $4,169,587 |
| 2022 | 968 | 133 | 7% (71) | None | $3,104,906 |
| 2021 | 978 | 106 | 14% (134) | 14% | $1,791,898 |
| 2020 | 617 | 85 | 13% (77) | 17% | $944,574 |
| 2019 | 614 | 132 | 7% (45) | 12% | $415,821 |
| 2018 | 483 | 139 | 7% (33) | 11% | $193,059 |
| 2017 | 402 | 114 | 9% (35) | 14% | $322,300 |
| 2016 | 127 | 36 | None | 31% | $144,476 |
| 2015 | 101 | 28 | 12% (12) | 17% | $55,121 |
| 2014 | 79 | 25 | None | 34% | $18,899 |
| 2013 | 358 | 32 | None | 25% | $27,932 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 32 drugs
| Revlimid | 59 | $1,417,502 | $24,025 |
| Imbruvica | 31 | $449,549 | $14,502 |
| Lenalidomide | 26 | $368,500 | $14,173 |
| Lynparza | 20 | $337,649 | $16,882 |
| Brukinsa | 16 | $226,284 | $14,143 |
| Tasigna | 12 | $213,190 | $17,766 |
| Abiraterone Acetate | 29 | $63,121 | $2,177 |
| Eliquis | 15 | $21,839 | $1,456 |
| Anagrelide | 12 | $9,973 | $831 |
| Anastrozole | 52 | $1,721 | $33 |
| Hydroxyurea | 25 | $1,297 | $52 |
| Tamoxifen Citrate | 33 | $1,237 | $37 |
| Dexamethasone | 48 | $1,077 | $22 |
| Potassium Chloride | 34 | $932 | $27 |
| Letrozole | 26 | $798 | $31 |
| Ondansetron | 45 | $748 | $17 |
| Prochlorperazine Maleate | 31 | $566 | $18 |
| Diphenoxylate-Atropine | 14 | $438 | $31 |
| Gabapentin | 15 | $438 | $29 |
| Escitalopram | 25 | $407 | $16 |
| Oxycodone | 17 | $394 | $23 |
| Venlafaxine | 11 | $360 | $33 |
| Morphine Sulfate Er | 16 | $355 | $22 |
| Methylphenidate | 12 | $342 | $28 |
| Baclofen | 11 | $331 | $30 |
| Tramadol | 21 | $263 | $13 |
| Prednisone | 29 | $255 | $9 |
| Trazodone | 16 | $240 | $15 |
| Lorazepam | 25 | $239 | $10 |
| Mirtazapine | 13 | $173 | $13 |
| Pantoprazole | 17 | $162 | $10 |
| Acyclovir | 15 | $42 | $3 |
2022: 25 drugs
| Revlimid | 77 | $1,493,065 | $19,390 |
| Imbruvica | 41 | $615,523 | $15,013 |
| Tasigna | 12 | $197,626 | $16,469 |
| Abiraterone Acetate | 35 | $83,426 | $2,384 |
| Xarelto | 19 | $13,741 | $723 |
| Anastrozole | 60 | $2,025 | $34 |
| Ondansetron | 54 | $1,761 | $33 |
| Hydrocodone-Acetaminophen | 17 | $1,165 | $69 |
| Dexamethasone | 34 | $874 | $26 |
| Hydroxyurea | 19 | $854 | $45 |
| Tamoxifen Citrate | 16 | $681 | $43 |
| Prednisone | 40 | $576 | $14 |
| Prochlorperazine Maleate | 29 | $543 | $19 |
| Duloxetine | 15 | $534 | $36 |
| Olanzapine | 19 | $460 | $24 |
| Oxycodone | 15 | $410 | $27 |
| Dextroamphetamine-Amphet Er | 14 | $392 | $28 |
| Tramadol | 13 | $345 | $27 |
| Potassium Chloride | 21 | $312 | $15 |
| Gabapentin | 22 | $230 | $10 |
| Trazodone | 20 | $180 | $9 |
| Lorazepam | 20 | $174 | $9 |
| Escitalopram | 18 | $165 | $9 |
| Amlodipine Besylate | 19 | $69 | $4 |
| Sertraline | 11 | $24 | $2 |
2021: 24 drugs
| Revlimid | 46 | $958,614 | $20,839 |
| Imbruvica | 22 | $330,189 | $15,009 |
| Abiraterone Acetate | 23 | $65,589 | $2,852 |
| Xarelto | 23 | $15,775 | $686 |
| Oxycodone | 48 | $1,745 | $36 |
| Dexamethasone | 56 | $1,521 | $27 |
| Ondansetron | 57 | $1,520 | $27 |
| Anastrozole | 44 | $1,345 | $31 |
| Hydroxyurea | 12 | $831 | $69 |
| Hydrocodone-Acetaminophen | 16 | $740 | $46 |
| Morphine Sulfate Er | 26 | $670 | $26 |
| Prochlorperazine Maleate | 51 | $642 | $13 |
| Tramadol | 29 | $567 | $20 |
| Acyclovir | 24 | $563 | $23 |
| Valacyclovir | 12 | $532 | $44 |
| Gabapentin | 40 | $522 | $13 |
| Lidocaine-Prilocaine | 24 | $464 | $19 |
| Prednisone | 45 | $301 | $7 |
| Buspirone | 15 | $250 | $17 |
| Trazodone | 18 | $235 | $13 |
| Sulfamethoxazole-Trimethoprim | 17 | $199 | $12 |
| Lorazepam | 42 | $165 | $4 |
| Escitalopram | 12 | $77 | $6 |
| Furosemide | 13 | $45 | $3 |
2020: 19 drugs
| Revlimid | 21 | $372,860 | $17,755 |
| Imbruvica | 14 | $221,992 | $15,857 |
| Lynparza | 12 | $186,470 | $15,539 |
| Abiraterone Acetate | 22 | $81,809 | $3,719 |
| Xarelto | 27 | $20,238 | $750 |
| Eliquis | 12 | $6,043 | $504 |
| Dexamethasone | 34 | $1,112 | $33 |
| Anastrozole | 27 | $921 | $34 |
| Ondansetron | 39 | $886 | $23 |
| Oxycodone | 22 | $778 | $35 |
| Morphine Sulfate Er | 17 | $674 | $40 |
| Prochlorperazine Maleate | 37 | $622 | $17 |
| Hydroxyurea | 11 | $523 | $48 |
| Acyclovir | 22 | $255 | $12 |
| Trazodone | 20 | $217 | $11 |
| Prednisone | 33 | $208 | $6 |
| Lorazepam | 49 | $158 | $3 |
| Zolpidem | 12 | $114 | $10 |
| Sulfamethoxazole-Trimethoprim | 13 | $34 | $3 |
2019: 15 drugs
| Revlimid | 12 | $131,093 | $10,924 |
| Abiraterone Acetate | 12 | $75,210 | $6,268 |
| Xarelto | 18 | $11,240 | $624 |
| Anastrozole | 112 | $3,387 | $30 |
| Tamoxifen Citrate | 46 | $2,655 | $58 |
| Hydroxyurea | 19 | $801 | $42 |
| Dexamethasone | 22 | $582 | $26 |
| Oxycodone | 17 | $518 | $30 |
| Prochlorperazine Maleate | 36 | $487 | $14 |
| Ondansetron | 33 | $455 | $14 |
| Lidocaine-Prilocaine | 17 | $407 | $24 |
| Letrozole | 14 | $265 | $19 |
| Prednisone | 28 | $235 | $8 |
| Trazodone | 13 | $177 | $14 |
| Lorazepam | 29 | $118 | $4 |
2018: 9 drugs
| Exemestane | 20 | $9,440 | $472 |
| Xarelto | 12 | $5,782 | $482 |
| Tamoxifen Citrate | 69 | $3,530 | $51 |
| Anastrozole | 122 | $3,452 | $28 |
| Letrozole | 17 | $358 | $21 |
| Lidocaine-Prilocaine | 11 | $273 | $25 |
| Lorazepam | 14 | $166 | $12 |
| Prochlorperazine Maleate | 11 | $114 | $10 |
| Gabapentin | 12 | $82 | $7 |
2017: 11 drugs
| Ibrance | 16 | $176,196 | $11,012 |
| Anastrozole | 65 | $2,507 | $39 |
| Tamoxifen Citrate | 50 | $2,166 | $43 |
| Lidocaine-Prilocaine | 16 | $508 | $32 |
| Letrozole | 17 | $358 | $21 |
| Oxycodone | 13 | $288 | $22 |
| Dexamethasone | 11 | $157 | $14 |
| Prochlorperazine Maleate | 20 | $150 | $8 |
| Gabapentin | 16 | $132 | $8 |
| Escitalopram | 11 | $93 | $8 |
| Lorazepam | 15 | $83 | $6 |
2016: 1 drug
| Anastrozole | 14 | $512 | $37 |
2015: 1 drug
| Anastrozole | 11 | $191 | $17 |
2014: 2 drugs
| Xopenex Hfa | 12 | $648 | $54 |
| Anastrozole | 11 | $172 | $16 |
2013: 11 drugs
| Novolog Flexpen | 11 | $3,201 | $291 |
| Gabapentin | 22 | $998 | $45 |
| Baclofen | 13 | $686 | $53 |
| Xopenex Hfa | 12 | $609 | $51 |
| Losartan | 25 | $519 | $21 |
| Lisinopril | 34 | $264 | $8 |
| Simvastatin | 15 | $129 | $9 |
| Amlodipine Besylate | 11 | $96 | $9 |
| Metformin | 11 | $70 | $6 |
| Trazodone | 11 | $45 | $4 |
| Single Use Swab | 11 | $34 | $3 |
Money from drug and device companies
$41 in 2023
| 2023 | 2 | 2 | None | $41 |
| 2022 | 2 | 3 | None | $175 |
| 2021 | 1 | 1 | None | $24 |
| 2020 | 1 | 1 | None | $12 |
| 2019 | 1 | 1 | None | $20 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Healthcare Solutions | Libtayo | $24 | 1 payment
|
| Daiichi Sankyo | Enhertu | $18 | 1 payment
|
See all 2 published payments
| Daiichi Sankyo | Meals · 2023-09-20 | Enhertu | $18 |
| Regeneron Healthcare Solutions | Meals · 2023-05-01 | Libtayo | $24 |
See earlier years (2022, 2021, 2020, 2019)
2022: $175
| Boston Scientific | Rezum Generator | $149 | 1 payment
|
| Acrotech Biopharma | Beleodaq | $26 | 2 payments
|
2021: $24
| Merck Sharp & Dohme | Keytruda | $24 | 1 payment
|
2020: $12
| Janssen Pharmaceuticals | Darzalex | $12 | 1 payment
|
2019: $20
| E.R. Squibb & Sons L.L.C. | Opdivo | $20 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 96.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1811213564
- Licence
- CA A159773California A159773: Current · expires 2028-12-31
- Trained
- University of Florida College of Medicine, 2010
- Group
- Monterey Bay Oncology A Medical Corporation · Dignity Health Medical Foundation
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 15400 National Ave Ste 201, Los Gatos, CA, 95032
- NPI first listed
- 2010-04-20
- NPI last updated
- 2026-05-14
- NPI record certified
- 2026-05-14
This is when the NPI record was last certified, not a medical board exam.